Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding insurance coverage timelines for its epinephrine nasal spray product 'neffy' with CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be eligible for compensation. The lead plaintiff deadline is October 5, 2026.

A class action lawsuit has been filed against ARS Pharmaceuticals (NYSE:SPRY) for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product 'neffy' with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to disclose risks of delays that would impact summer and back-to-school seasons. Investors who purchased ARS securities between March 9 and June 24, 2026 can apply to be lead plaintiff by October 5, 2026.

Rosen Law Firm is reminding investors who purchased ARS Pharmaceuticals securities between March 9, 2026 and June 24, 2026 of an October 5, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product (neffy) through CVS Caremark, causing investors to purchase securities at artificially inflated prices.

Rosen Law Firm is notifying investors in EquipmentShare.com Inc, ARS Pharmaceuticals Inc, and Barclays PLC of ongoing securities class action lawsuits. EquipmentShare investors who purchased shares during the IPO or within the Class Period are encouraged to join the lawsuit, with a lead plaintiff deadline of September 21, 2026. The lawsuits allege material misstatements and omissions regarding business operations and financial disclosures.

A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product neffy through CVS Caremark. The company failed to disclose risks that the July 1, 2026 coverage deadline might not be met. When the truth emerged on June 24, 2026, ARS stock declined over 23.9% in a single day.

Law firm Levi & Korsinsky has filed a class action lawsuit against ARS Pharmaceuticals for allegedly making false and misleading statements regarding expanded insurance coverage for its drug neffy through CVS Caremark. The company failed to meet its July 1, 2026 deadline for coverage expansion, causing the stock to plummet 23.9% on June 25, 2026. Investors who purchased securities between March 9 and June 24, 2026 can join the lawsuit with a lead plaintiff deadline of October 5, 2026.

ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7 million, with neffy (epinephrine nasal spray) generating $17.5 million in U.S. net product revenue. The company expanded its sales force to 148 representatives, secured approval from Health Canada, and achieved European Commission marketing authorization for EURneffy 1 mg. CVS Caremark formulary approval is in final stages with expected July 2026 effective date. The Phase 2b CSU trial interim population is fully enrolled with Q4 2026 readout expected. Despite strong commercial momentum, the company reported a net loss of $60.6 million for the quarter.

ARS Pharmaceuticals (Nasdaq: SPRY) announced a conference call scheduled for May 15, 2026, to discuss its first quarter 2026 financial results and business highlights. The company continues commercializing neffy®, an epinephrine nasal spray for emergency treatment of allergic reactions and anaphylaxis across multiple markets including the U.S., EU, and China.

ARS Pharmaceuticals reported $32.5 million in revenue for Q3 2025, primarily from neffy epinephrine nasal spray sales. The company continues to expand market presence through direct-to-consumer campaigns and has strong cash reserves of $288.2 million.

ARS Pharmaceuticals reported strong Q2 2025 revenue of $15.7 million, driven by its needle-free epinephrine nasal spray neffy. Prescription volumes grew 180%, and commercial coverage reached 93%, though high operating costs led to a net loss of $44.9 million.

ARS Pharmaceuticals has filed for approval of its epinephrine nasal spray 'neffy' in Canada and the United Kingdom, where it will be marketed as 'EURneffy', on behalf of its licensing partner ALK-Abelló A/S. The filing is part of the company's efforts to expand the global availability of this life-saving treatment for severe allergic reactions.

ARS Pharmaceuticals announced that its licensing partners in China, Japan, and Australia have filed for regulatory approval of its epinephrine nasal spray, neffy, for the treatment of type I allergic reactions including anaphylaxis. The company is focused on making this life-saving treatment widely available globally.